Skip to content

Study · Randomized controlled trial · n = 12 · 1994

10 results

Growth hormone-releasing activity of hexarelin in humans. A dose-response study.

Imbimbo BP, Mant T, Edwards M, Amin D, Dalton N, Boutignon F, Lenaerts V, Wüthrich P, Deghenghi R

European journal of clinical pharmacology1 Jan 1994Cited by 30 (Europe PMC)

PMID7957536 (opens in a new tab)DOI10.1007/bf00191904 (opens in a new tab)PepBankPUB-07957536
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In healthy men, plasma growth hormone increased dose-dependently after intravenous hexarelin.

    In plain wordsIn healthy men, hexarelin raised growth hormone in the blood, and higher doses raised it more.

    Peptide
    Hexarelin
    Outcome
    IncreasePlasma GH after hexarelin injection
    Study

    n = 12

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.5, 1 and 2 micrograms/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    Plasma growth hormone concentrations increased dose-dependently after the injection of the peptide
    2 context sentences
    Summary · context
    In this double-blind, placebo-controlled, rising-dose study we evaluated the growth hormone releasing activity of hexarelin in healthy human subjects.
    Summary · context
    Twelve adult male volunteers received single intravenous boluses of 0.5, 1 and 2.micrograms.kg-1 hexarelin as well as placebo.
  2. 02HumanRandomized controlled trialEfficacy outcome

    Plasma GH peaked at about 30 min and returned to baseline within 240 min, with a half-life of about 55 min.

    In plain wordsAfter hexarelin, growth hormone in the blood peaked at about 30 minutes and went back to baseline within 240 minutes.

    Peptide
    Hexarelin
    Outcome
    Not applicableTime course of plasma GH after hexarelin
    Study

    n = 12

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.5, 1 and 2 micrograms/kg · intravenousAs given in this study (human).

    Measurements

    Time to peak
    ≈ 30 min
    plasma GH
    Half-life
    ≈ 55 min
    plasma GH

    Source sentences

    Summary
    peaking at about 30 min and then decreasing to baseline values within 240 min with a half-life of about 55 min.
    2 context sentences
    Summary · context
    In this double-blind, placebo-controlled, rising-dose study we evaluated the growth hormone releasing activity of hexarelin in healthy human subjects.
    Summary · context
    Twelve adult male volunteers received single intravenous boluses of 0.5, 1 and 2.micrograms.kg-1 hexarelin as well as placebo.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In healthy men, the mean peak plasma GH was 26.9 ng/ml after hexarelin 0.5 microgram/kg and 3.9 ng/ml after placebo.

    In plain wordsIn healthy men, the peak growth hormone level after the lowest hexarelin dose was higher than after placebo.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH Cmax at 0.5 microgram/kg
    Study

    n = 12

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.5 microgram/kg · intravenousAs given in this study (human).

    Measurements

    Cmax
    26.9 ng.ml-1
    0.5 micrograms.kg-1
    Cmax
    3.9 ng.ml-1
    placebo

    Source sentences

    Summary
    The mean peak plasma growth hormone concentrations (Cmax) were 3.9, 26.9, 52.3, 55.0 ng.ml-1 after 0, 0.5, 1 and 2 micrograms.kg-1, respectively.
    2 context sentences
    Summary · context
    In this double-blind, placebo-controlled, rising-dose study we evaluated the growth hormone releasing activity of hexarelin in healthy human subjects.
    Summary · context
    Twelve adult male volunteers received single intravenous boluses of 0.5, 1 and 2.micrograms.kg-1 hexarelin as well as placebo.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In healthy men, the mean peak plasma GH was 52.3 ng/ml after hexarelin 1 microgram/kg and 3.9 ng/ml after placebo.

    In plain wordsIn healthy men, the peak growth hormone level after the middle hexarelin dose was higher than after placebo.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH Cmax at 1 microgram/kg
    Study

    n = 12

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 microgram/kg · intravenousAs given in this study (human).

    Measurements

    Cmax
    52.3 ng.ml-1
    1 micrograms.kg-1
    Cmax
    3.9 ng.ml-1
    placebo

    Source sentences

    Summary
    The mean peak plasma growth hormone concentrations (Cmax) were 3.9, 26.9, 52.3, 55.0 ng.ml-1 after 0, 0.5, 1 and 2 micrograms.kg-1, respectively.
    2 context sentences
    Summary · context
    In this double-blind, placebo-controlled, rising-dose study we evaluated the growth hormone releasing activity of hexarelin in healthy human subjects.
    Summary · context
    Twelve adult male volunteers received single intravenous boluses of 0.5, 1 and 2.micrograms.kg-1 hexarelin as well as placebo.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In healthy men, the mean peak plasma GH was 55.0 ng/ml after hexarelin 2 micrograms/kg and 3.9 ng/ml after placebo.

    In plain wordsIn healthy men, the peak growth hormone level after the highest hexarelin dose was higher than after placebo.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH Cmax at 2 micrograms/kg
    Study

    n = 12

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 micrograms/kg · intravenousAs given in this study (human).

    Measurements

    Cmax
    55 ng.ml-1
    2 micrograms.kg-1
    Cmax
    3.9 ng.ml-1
    placebo

    Source sentences

    Summary
    The mean peak plasma growth hormone concentrations (Cmax) were 3.9, 26.9, 52.3, 55.0 ng.ml-1 after 0, 0.5, 1 and 2 micrograms.kg-1, respectively.
    2 context sentences
    Summary · context
    In this double-blind, placebo-controlled, rising-dose study we evaluated the growth hormone releasing activity of hexarelin in healthy human subjects.
    Summary · context
    Twelve adult male volunteers received single intravenous boluses of 0.5, 1 and 2.micrograms.kg-1 hexarelin as well as placebo.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In healthy men, the GH area under the curve to 180 min was 1.412 after hexarelin 0.5 microgram/kg and 0.135 after placebo.

    In plain wordsIn healthy men, total growth hormone exposure after the lowest hexarelin dose was higher than after placebo.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH AUC0-180 at 0.5 microgram/kg
    Study

    n = 12

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.5 microgram/kg · intravenousAs given in this study (human).

    Measurements

    AUC0-180
    1.412 micrograms.min.ml-1
    0.5 microgram/kg
    AUC0-180
    0.135 micrograms.min.ml-1
    placebo

    Source sentences

    Summary
    The corresponding areas under the curve of growth hormone plasma levels from drug injection to 180 min (AUC0-180) were 0.135, 1.412, 2.918 and 3.695 micrograms.min.ml-1.
    2 context sentences
    Summary · context
    In this double-blind, placebo-controlled, rising-dose study we evaluated the growth hormone releasing activity of hexarelin in healthy human subjects.
    Summary · context
    Twelve adult male volunteers received single intravenous boluses of 0.5, 1 and 2.micrograms.kg-1 hexarelin as well as placebo.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In healthy men, the GH area under the curve to 180 min was 2.918 after hexarelin 1 microgram/kg and 0.135 after placebo.

    In plain wordsIn healthy men, total growth hormone exposure after the middle hexarelin dose was higher than after placebo.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH AUC0-180 at 1 microgram/kg
    Study

    n = 12

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 microgram/kg · intravenousAs given in this study (human).

    Measurements

    AUC0-180
    2.918 micrograms.min.ml-1
    1 microgram/kg
    AUC0-180
    0.135 micrograms.min.ml-1
    placebo

    Source sentences

    Summary
    The corresponding areas under the curve of growth hormone plasma levels from drug injection to 180 min (AUC0-180) were 0.135, 1.412, 2.918 and 3.695 micrograms.min.ml-1.
    2 context sentences
    Summary · context
    In this double-blind, placebo-controlled, rising-dose study we evaluated the growth hormone releasing activity of hexarelin in healthy human subjects.
    Summary · context
    Twelve adult male volunteers received single intravenous boluses of 0.5, 1 and 2.micrograms.kg-1 hexarelin as well as placebo.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In healthy men, the GH area under the curve to 180 min was 3.695 after hexarelin 2 micrograms/kg and 0.135 after placebo.

    In plain wordsIn healthy men, total growth hormone exposure after the highest hexarelin dose was higher than after placebo.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH AUC0-180 at 2 micrograms/kg
    Study

    n = 12

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 micrograms/kg · intravenousAs given in this study (human).

    Measurements

    AUC0-180
    3.695 micrograms.min.ml-1
    2 micrograms/kg
    AUC0-180
    0.135 micrograms.min.ml-1
    placebo

    Source sentences

    Summary
    The corresponding areas under the curve of growth hormone plasma levels from drug injection to 180 min (AUC0-180) were 0.135, 1.412, 2.918 and 3.695 micrograms.min.ml-1.
    2 context sentences
    Summary · context
    In this double-blind, placebo-controlled, rising-dose study we evaluated the growth hormone releasing activity of hexarelin in healthy human subjects.
    Summary · context
    Twelve adult male volunteers received single intravenous boluses of 0.5, 1 and 2.micrograms.kg-1 hexarelin as well as placebo.
  9. 09HumanRandomized controlled trialActivity measurement

    Logistic regression gave ED50 values of 0.50 microgram/kg for Cmax and 0.64 microgram/kg for AUC0-180.

    In plain wordsIn healthy men, about half of the maximal growth hormone response occurred at hexarelin doses near 0.5 to 0.64 micrograms per kilogram.

    Peptide
    Hexarelin
    Outcome
    Not applicableED50 of hexarelin for GH release
    Study

    n = 12

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.5, 1 and 2 micrograms/kg · intravenousAs given in this study (human).

    Measurements

    ED50
    0.5 microgram.kg-1
    Cmax
    ED50
    0.64 microgram.kg-1
    AUC0-180

    Source sentences

    Summary
    The calculated ED50 values were 0.50 and 0.64 microgram.kg-1 for Cmax and AUC0-180, respectively.
    2 context sentences
    Summary · context
    In this double-blind, placebo-controlled, rising-dose study we evaluated the growth hormone releasing activity of hexarelin in healthy human subjects.
    Summary · context
    Twelve adult male volunteers received single intravenous boluses of 0.5, 1 and 2.micrograms.kg-1 hexarelin as well as placebo.
  10. 10HumanRandomized controlled trialActivity measurement

    The estimated Emax values were 55.1 ng/ml for Cmax and 3936 ng.min/ml for AUC0-180, so the 2 micrograms/kg dose is close to the maximal response.

    In plain wordsIn healthy men, the highest hexarelin dose gave a growth hormone response close to the maximum.

    Peptide
    Hexarelin
    Outcome
    Not applicableEmax of hexarelin for GH release
    Study

    n = 12

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.5, 1 and 2 micrograms/kg · intravenousAs given in this study (human).

    Measurements

    Emax
    55.1 ng.ml-1
    Cmax
    Emax
    3936 ng.min.ml-1
    AUC0-180

    Source sentences

    Summary
    The corresponding Emaxs were 55.1 ng.ml-1 and 3936 ng.min.ml-1, thus indicating that the effect after the 2 micrograms.kg-1 dose is very close to the maximal response
    2 context sentences
    Summary · context
    In this double-blind, placebo-controlled, rising-dose study we evaluated the growth hormone releasing activity of hexarelin in healthy human subjects.
    Summary · context
    Twelve adult male volunteers received single intravenous boluses of 0.5, 1 and 2.micrograms.kg-1 hexarelin as well as placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.